159 related articles for article (PubMed ID: 27506827)
21. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
Behm B; Di Fazio P; Michl P; Neureiter D; Kemmerling R; Hahn EG; Strobel D; Gress T; Schuppan D; Wissniowski TT
Gut; 2016 Jan; 65(1):134-43. PubMed ID: 25524262
[TBL] [Abstract][Full Text] [Related]
22. Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma.
Ambade AV; Joshi GV; Mulherkar R
Indian J Med Res; 2010 Oct; 132():415-22. PubMed ID: 20966520
[TBL] [Abstract][Full Text] [Related]
23. In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas.
Shibata MA; Ito Y; Morimoto J; Kusakabe K; Yoshinaka R; Otsuki Y
J Gene Med; 2006 Mar; 8(3):335-52. PubMed ID: 16345101
[TBL] [Abstract][Full Text] [Related]
24. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth.
Tamura T; Nishi T; Goto T; Takeshima H; Ushio Y; Sakata T
Anticancer Res; 2003; 23(2B):1173-9. PubMed ID: 12820368
[TBL] [Abstract][Full Text] [Related]
25. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
26. Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.
Ziekman PG; Otter WD; Tan JF; Teske E; Kirpensteijn J; Koten JW; Jacobs JJ
Anticancer Res; 2013 Jan; 33(1):161-5. PubMed ID: 23267141
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
28. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
29. A combination of electrochemotherapy, gene electrotransfer of plasmid encoding canine IL-12 and cytoreductive surgery in the treatment of canine oral malignant melanoma.
Milevoj N; Tratar UL; Nemec A; Brožič A; Žnidar K; Serša G; Čemažar M; Tozon N
Res Vet Sci; 2019 Feb; 122():40-49. PubMed ID: 30453179
[TBL] [Abstract][Full Text] [Related]
30. Genetic immunotherapy for cancer.
Elmslie RE; Dow SW
Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):193-205. PubMed ID: 9283245
[TBL] [Abstract][Full Text] [Related]
31. Safety and feasibility of the NanoKnife system for irreversible electroporation ablative treatment of canine spontaneous intracranial gliomas.
Rossmeisl JH; Garcia PA; Pancotto TE; Robertson JL; Henao-Guerrero N; Neal RE; Ellis TL; Davalos RV
J Neurosurg; 2015 Oct; 123(4):1008-25. PubMed ID: 26140483
[TBL] [Abstract][Full Text] [Related]
32. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision.
Lowe R; Gavazza A; Impellizeri JA; Soden DM; Lubas G
Vet Comp Oncol; 2017 Sep; 15(3):775-784. PubMed ID: 27001443
[TBL] [Abstract][Full Text] [Related]
33. Electroporation in veterinary oncology.
Impellizeri J; Aurisicchio L; Forde P; Soden DM
Vet J; 2016 Nov; 217():18-25. PubMed ID: 27810205
[TBL] [Abstract][Full Text] [Related]
34. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
[TBL] [Abstract][Full Text] [Related]
37. Electroporation gene therapy preclinical and clinical trials for melanoma.
Heller LC; Heller R
Curr Gene Ther; 2010 Aug; 10(4):312-7. PubMed ID: 20557286
[TBL] [Abstract][Full Text] [Related]
38. Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells.
Mlakar V; Todorovic V; Cemazar M; Glavac D; Sersa G
BMC Cancer; 2009 Aug; 9():299. PubMed ID: 19709437
[TBL] [Abstract][Full Text] [Related]
39. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours.
Kodre V; Cemazar M; Pecar J; Sersa G; Cor A; Tozon N
In Vivo; 2009; 23(1):55-62. PubMed ID: 19368125
[TBL] [Abstract][Full Text] [Related]
40. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.
Mansurov A; Ishihara J; Hosseinchi P; Potin L; Marchell TM; Ishihara A; Williford JM; Alpar AT; Raczy MM; Gray LT; Swartz MA; Hubbell JA
Nat Biomed Eng; 2020 May; 4(5):531-543. PubMed ID: 32284554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
